EG-GILERO, a leader for design, development and contract manufacturing services within the medical device, drug delivery device, and primary pharmaceutical packaging markets, announced at the MD&M East 2016 Exposition in New York, NY, a major expanded investment in the state-of-the-art Shenzhen, China facility previously branded under Medacys.

“China is encouraging local R&D and local manufacturing, particularly on high-value medical products such as drug delivery and medical devices, not just to be a supplier of components to the device world, but to be a manufacturer of finished devices for the local market,” said Larry Jutte, President & COO of EG Industries.

With 60,000+ square feet of product design and development resources, in-house tool building, scientific injection molding capabilities, and both automated and manual assembly capabilities, EG-MEDACYS is well positioned to provide support for our customers seeking entry in this rapidly growing market. Part of this strategic localization effort includes expansion of capabilities with the addition of Liquid Silicone Rubber (LSR) injection molding and more in the coming months.

“The Chinese medical technology market is expected to grow at double digit rates in the coming years,” explained Tim Hopper, CMO of EG-GILERO. “Our investment in our Shenzhen, China facility will allow us to provide our clients with an outsourced solution that provides an OEM product line to the Chinese market. The facility also provides a responsive, high quality, and lower cost option to source tooling, molding, and assembly for utilization across the globe at a world-class level,” he added.

EG-GILERO continues executing on its strategy to offer customers options to commercialize their device domestically in the United States or in a lower-cost country such as China with an unwavering commitment to quality, as well as provide proper representation in other strategic areas of the globe.